HighTower Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

HighTower Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Sell	2,708 -94	-3%	-$7.54K	﹤0.01%	3453
2026 Q1	$215K	Buy	+2,802	New	+$219K	﹤0.01%	3430
2025 Q4	–	Sell	-4,969	Closed	-$455K	–	3667
2025 Q3	$455K	Buy	+4,969	New	+$405K	﹤0.01%	2698
2024 Q4	–	Sell	-3,613	Closed	-$222K	–	3818
2024 Q3	$222K	Buy	+3,613	New	+$220K	﹤0.01%	3062
2024 Q2	–	Sell	-2,887	Closed	-$205K	–	3688
2024 Q1	$205K	Buy	+2,887	New	+$174K	﹤0.01%	2970
2019 Q3	–	Sell	-2,614	Closed	-$214K	–	2411
2019 Q2	$214K	Buy	+2,614	New	+$186K	﹤0.01%	2014
2016 Q4	–	Sell	-3,050	Closed	-$202K	–	1938
2016 Q3	$202K	Buy	+3,050	New	+$191K	﹤0.01%	1645
2016 Q2	–	Sell	-10,588	Closed	-$348K	–	1775
2016 Q1	$348K	Buy	+10,588	New	+$359K	﹤0.01%	1548

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's ANIP Position: Q2 2026 in Review

HighTower Advisors reduced its ANI Pharmaceuticals (ANIP) stake by 3.4% in Q2 2026, selling an estimated $7.54K and leaving 2,708 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #3453.

HighTower Advisors first reported a position in ANIP in Q1 2016 and has held it in 8 quarters since. The position peaked at $455K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

HighTower Advisors held 2,708 shares of ANI Pharmaceuticals worth $224K as of Q2 2026.
HighTower Advisors sold 94 ANI Pharmaceuticals shares in Q2 2026, an estimated $7.54K.
ANI Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3453 holding.
HighTower Advisors first reported a position in ANI Pharmaceuticals in Q1 2016 and has held it in 8 quarters since.
HighTower Advisors's ANI Pharmaceuticals position peaked at $455K in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.